Advanced SearchSearch Tips
Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study
Takemoto, Shigeki; Iwanaga, Masako; Sagara, Yasuko; Watanabe, Toshiki;
  PDF(new window)
Elevated levels of soluble CD30 (sCD30) are linked with various T-cell neoplasms. However, the relationship between sCD30 levels and the development of adult T-cell leukemia (ATL) in human T-cell leukemia virus type 1 (HTLV-1) carriers remains to be clarified. We here investigated whether plasma sCD30 is associated with risk of ATL in a nested case-control study within a cohort of HTLV-1 carriers. We compared sCD30 levels between 11 cases (i.e., HTLV-1 carriers who later progressed to ATL) and 22 age-, sex- and institution-matched control HTLV-1 carriers (i.e., those with no progression). The sCD30 concentration at baseline was significantly higher in cases than in controls (median 65.8, range 27.2-134.5 U/mL vs. median 22.2, range 8.4-63.1 U/mL, P
Adult T-cell leukemia (ATL);CD30;human T-cell leukemia virus type 1 (HTLV-1);
 Cited by
Human T-cell lymphotropic virus type 1 and its oncogenesis, Acta Pharmacologica Sinica, 2017, 38, 8, 1093  crossref(new windwow)
Anagnostopoulos I, Hummel M, Kaudewitz P, et al (1990). Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas. Am J Pathol, 137, 1317-22.

Breen EC, Fatahi S, Epeldegui M, et al (2006). Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol, 27, 187-94. crossref(new window)

Caligaris-Cappio F, Bertero MT, Converso M, et al (1995). Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol, 13, 339-43.

Franchini G (1995). Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood, 86, 3619-39.

Gause A, Pohl C, Tschiersch A, et al (1991). Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood, 77, 1983-8.

Gerli R, Muscat C, Bistoni O, et al (1995). High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol, 102, 547-50.

Giacomelli R, Cirripani P, Lattazio R, et al (1997). Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of disease. Clin Exp Immunol, 108, 42-6. crossref(new window)

Higuchi M, Matsuda T, Mori N, et al (2005). Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. Retrovirol, 2, 29. crossref(new window)

Horie R, Watanabe T (1998). CD30: expression and function in health and disease. Semin Immunol, 10, 457-70. crossref(new window)

Iwanaga M, Watanabe T, Utsunomiya A, et al (2010). Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood, 116, 1211-9. crossref(new window)

Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM (1996). Elevations in IFN-${\gamma}$, IL-5, and IL-10 in patients with the autoimmune primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immonopathol, 80, 311-20. crossref(new window)

Michai M, Goto H, Hattori S, et al (2012). Soluble CD30: a possible serum tumor marker for primary effusion lymphoma. Asian Pac J Cancer Prev, 13, 4939-41. crossref(new window)

Muta H, Podack ER (2013). CD30: from basic research to cancer therapy. Immunol Res, 57, 151-8. crossref(new window)

Nakada K, Kohakura M, Komoda H, Hinuma Y (1984). High incidence of HTLV antibody in carriers of Strongyloides stercoralis. Lancet, 1, 633.

Nishioka C, Takemoto S, Kataoka S, et al (2005). Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci, 96, 810-5. crossref(new window)

Ohtsuka E, Kikuchi H, Nasu M, et al (1994). Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma, 15, 303-10. crossref(new window)

Okamoto T, Ohno Y, Tsugane S, et al (1989). Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res; 80: 191-195. crossref(new window)

Pfreundschuh M, Pohl C, Berenbeck C, et al (1990). Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer, 45, 869-74. crossref(new window)

Pornkuna R, Takemoto S, Hidaka M, Kawano F, Haga Y (2014a). Clinical value of serum soluble CD30 levels in adult T-cell leukemia/lymphoma. J Hematol Thrombo Dis, 2, 167.

Pornkuna R, Nishioka C, Takemoto S (2014b). What is the role of soluble cytokine receptors in adult T-cell leukemia/ lymphoma? J Hematol Thrombo Dis, 2, 154.

Purdue MP, Lan Q, Martinez-Maza O, et al (2009). A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood, 114, 2730-2. crossref(new window)

Shimoyama M (1991). Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol, 79, 428-37. crossref(new window)

Takatsuki K, Yamaguchi K, Kawano F, et al (1985). Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res, 45, 4644-5.

Takemoto S, Matsuoka M, Yamaguchi K, Takatsuki K (1994). A novel diagnostic method of adult T-cell leukemia: Monoclonal integration of human T-cell lymphotropic virus type I proviral DNA detected by inverse polymerase chain reaction. Blood, 84, 3080-5.

Takemoto S, Morimatsu Y, Pornkuna R, Murayama T, Kawano F (2014). CD30+ cells in lung of indolent type adult T-cell leukemia/lymphoma and elevated serum levels of soluble CD30 associated with acute crisis and relapse of disease. J Leuk, 2, 166.

Takeshita M, Akamatsu M, Ohshima K, et al (1995). CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathol, 26, 539-46. crossref(new window)

Tang C, Yamada H, Shibata K, et al (2008). A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol, 181, 6316-27. crossref(new window)

Trinchieri G (2012). Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol, 30, 677-706. crossref(new window)

Tsukasaki K, Tsushima H, Yamamura M, et al (1997). Integration patterns of HTLV-I proviral in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood, 89, 948-56.

Uchiyama T, Yodoi J, Segawa K, Uchino H (1977). Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood, 50, 481-92.

Yamaguchi K (1994). Human T-lymphotropic virus type I in Japan. Lancet, 343, 213-6. crossref(new window)

Yoshida M, Miyoshi I, Hinuma Y (1982). Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. PNAS, 79, 2031-5. crossref(new window)

Zhao T, Matsuoka M (2012). HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol, 3, 247.